Wencai Zhang1, Tingting Tang1, Daan Nie1, Shuang Wen1, Chenping Jia1, Zhengfeng Zhu1, Ni Xia1, Shaofang Nie1, Sufeng Zhou1, Jiao Jiao1, Wenyong Dong1, Bingjie Lv1, Tongjie Xu2, Bing Sun2, Yuzhi Lu1, Yuanyuan Li1, Longxian Cheng1, Yuhua Liao1, Xiang Cheng3. 1. Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Wuhan 430022, China. 2. Key Laboratory of Molecular Biophysics of Ministry of Education, School of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China. 3. Laboratory of Cardiovascular Immunology, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430022, China Key Laboratory of Biological Targeted Therapy of the Ministry of Education, Wuhan 430022, China nathancx@mail.hust.edu.cn.
Abstract
AIMS: Recently, interleukin (IL)-9 was found to be involved in the pathogenesis of many inflammatory diseases. Here, we tested whether IL-9 was related to atherosclerosis and investigated the underlying mechanisms. METHODS AND RESULTS: IL-9R was expressed in mouse aortic endothelial cells (MAECs) and aortic tissues, and IL-9 levels were elevated in plasma and aortic arches in Apolipoprotein E-deficient (ApoE-/-) mice. ApoE-/- mice fed a western diet for 10 weeks were administered recombinant mouse IL-9 (rIL-9) or anti-IL-9 neutralizing monoclonal antibody (mAb). Mice treated with rIL-9 developed markedly larger plaques in both the aorta and aortic root. Immunohistochemical studies demonstrated increases in both vascular endothelial adhesion molecule-1 (VCAM-1) expression and the infiltration of inflammatory cells, including T cells and macrophages, in plaques. However, treatment with the anti-IL-9 mAb caused the opposite effect. The administration of rIL-9 did not affect the splenic T cell or peripheral monocyte subsets. Meanwhile, IL-9 induced VCAM-1 expression in MAECs mainly via a STAT3-dependent pathway, consequently increasing monocyte-endothelial adhesion. Moreover, treatment with anti-VCAM-1 mAb partially abrogated the IL-9-induced increase in plaque area. In addition, CD4(+)IL-9(+) T cells and IL-9 were increased in patients with acute coronary syndrome, and the levels of IL-9 in culture supernatants and soluble VCAM-1 (sVCAM-1) in plasma were significantly positively correlated in the enrolled patients. CONCLUSION: Our results demonstrated that IL-9 exerted pro-atherosclerotic effects in ApoE-/- mice at least partially by inducing VCAM-1 expression, which mediated inflammatory cell infiltration into atherosclerotic lesions. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Recently, interleukin (IL)-9 was found to be involved in the pathogenesis of many inflammatory diseases. Here, we tested whether IL-9 was related to atherosclerosis and investigated the underlying mechanisms. METHODS AND RESULTS:IL-9R was expressed in mouse aortic endothelial cells (MAECs) and aortic tissues, and IL-9 levels were elevated in plasma and aortic arches in Apolipoprotein E-deficient (ApoE-/-)mice. ApoE-/- mice fed a western diet for 10 weeks were administered recombinant mouseIL-9 (rIL-9) or anti-IL-9 neutralizing monoclonal antibody (mAb). Mice treated with rIL-9 developed markedly larger plaques in both the aorta and aortic root. Immunohistochemical studies demonstrated increases in both vascular endothelial adhesion molecule-1 (VCAM-1) expression and the infiltration of inflammatory cells, including T cells and macrophages, in plaques. However, treatment with the anti-IL-9 mAb caused the opposite effect. The administration of rIL-9 did not affect the splenic T cell or peripheral monocyte subsets. Meanwhile, IL-9 induced VCAM-1 expression in MAECs mainly via a STAT3-dependent pathway, consequently increasing monocyte-endothelial adhesion. Moreover, treatment with anti-VCAM-1 mAb partially abrogated the IL-9-induced increase in plaque area. In addition, CD4(+)IL-9(+) T cells and IL-9 were increased in patients with acute coronary syndrome, and the levels of IL-9 in culture supernatants and soluble VCAM-1 (sVCAM-1) in plasma were significantly positively correlated in the enrolled patients. CONCLUSION: Our results demonstrated that IL-9 exerted pro-atherosclerotic effects in ApoE-/- mice at least partially by inducing VCAM-1 expression, which mediated inflammatory cell infiltration into atherosclerotic lesions. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Rulin Zhuang; Jingshu Chen; Henry S Cheng; Carmel Assa; Anurag Jamaiyar; Arvind K Pandey; Daniel Pérez-Cremades; Bofang Zhang; Aspasia Tzani; Akm Khyrul Wara; Jorge Plutzky; Victor Barrera; Preetida Bhetariya; Richard N Mitchell; Zhongmin Liu; Mark W Feinberg Journal: Circ Res Date: 2022-04-20 Impact factor: 23.213
Authors: Lisheng Zhang; Jiao-Hui Wu; James C Otto; Susan B Gurley; Elizabeth R Hauser; Sudha K Shenoy; Karim Nagi; Leigh Brian; Virginia Wertman; Natalie Mattocks; Jeffrey H Lawson; Neil J Freedman Journal: Cardiovasc Res Date: 2017-11-01 Impact factor: 10.787
Authors: Xiaoyan Min; Miao Lu; Su Tu; Xiangming Wang; Chuanwei Zhou; Sen Wang; Sisi Pang; Jin Qian; Yiyue Ge; Yan Guo; Di Xu; Kejiang Cao Journal: Biomed Res Int Date: 2017-03-02 Impact factor: 3.411
Authors: Byung Soo Kong; Soo Jung Im; Yang Jong Lee; Yoon Hee Cho; Yu Ri Do; Jung Woo Byun; Cheol Ryong Ku; Eun Jig Lee Journal: PLoS One Date: 2016-03-22 Impact factor: 3.240